Alcon Acquires Lensar for $430 Million to Advance Smart Cataract Surgery Solutions

Mar 25, 2025 16:59 CST Updated 16:59

LENSAR

Femtosecond Laser System Developer

Global Ophthalmic Care Sector Welcomes Major Deal — Ophthalmology Giant Alcon Announces Acquisition of$430 million (approximately 3.1 billion RMB)Acquisition of LENSAR, Inc., a U.S. laser-assisted cataract surgery company.

This transaction aims to integrate Lensar's innovative laser technology, further enhancing the precision and efficiency of cataract surgery. As the world’s largest ophthalmic medical device company, Alcon accelerates its transformation from traditional equipment to intelligent and digital solutions through this acquisition, reinforcing its leadership position in the laser surgery field.

Absolute Giant VS Industry Rising Star

Absolute Giant: Elcon

Alcon was founded in 1945, with its headquarters located in Geneva, Switzerland. Its business covers 75 countries worldwide. Its core products include the AcrySof series of intraocular lenses, which have been implanted globally.Over 100 Million Tablets, high-end equipment such as phacoemulsification machines and vitrectomy machines,Accounting for approximately 30% of the global market share。

After spinning off from Novartis in 2019, the company strengthened its technical barriers through strategic acquisitions. In 2023, it ranked 17th in the global medical device brand value list, with annual revenue exceeding 2.4 billion US dollars.

IndustryNew Nobility：Lensar

LENSAR, Inc. was founded in 2007 and focuses on the research and development of femtosecond laser cataract surgery equipment.

Its flagship product, ALLY® Adaptive Cataract Laser Treatment System, integrates dual-pulse femtosecond laser with AR imaging technology, enabling intraoperative lens density analysis, personalized fragmentation pattern planning, and corneal incision optimization.Shorten traditional surgery time by more than 30%。

Compared with competitive products such as Medtronic and Henan Elcon Technology Co., Ltd., the ALLY system is renowned for its compact design (occupying only 0.58 square meters), high compatibility, and ease of operation, making it suitable for various operating room environments.

The system received FDA approval in June 2022 and has been applied in top global ophthalmic institutions. In August 2024, it obtained EU CE certification, accelerating its entry into the European market, and is regarded as a milestone in the intelligence of cataract surgery.

In Q3 2024, it accounted for 21% of the global laser-assisted cataract surgery (LACS) market share, with a growth rate of 45% in the U.S. market.

Is 3.1 billion worth it?

Despite LENSAR currently still being in a loss-making phase(Revenue of $36.76 million in Q3 2024, net loss of $12.7 million), but LENSAR still holds an important position in the global ophthalmic femtosecond laser market, with its ALLY system showing strong sales growth potential in the U.S. and international markets.

ALLY System, as the world's first cataract treatment platform integrating AR and femtosecond laser, its "Adaptive Intelligence" algorithm can reduce surgical energy consumption, aligning with the trend of precision medicine.

Currently, the annual growth rate of cataract surgeries worldwide shows a significant upward trend. However, the penetration rate of laser-assisted procedures accounts for only 30%-40% even in developed countries. But with the advancement of technology and the expansion of medical insurance coverage, the surgery rate in developing countries is expected to increase rapidly, and LENSAR's technology may drive industry upgrades.

As the market share expands and operational efficiency improves, LENSAR's valuation is expected to rise significantly in the coming years.

For industry giant Alcon, the cost of directly acquiring Lensar is much lower than independently developing equivalent technology.

Upon the successful completion of the acquisition, Elcon can complement its existing phacoemulsification system with LENSAR laser technology.Build a full-chain solution for "preoperative diagnosis - laser cutting - phacoemulsification - intraocular lens implantation", further strengthening the technical barriers while more effectively consolidating Elcon's leading position.

Review of Alcon's M&A History

A review of Alcon's recent M&A cases shows that technology-driven acquisitions tend to be highly effective:

Acquisition of Summit Autonomous in 2000: Obtained excimer laser technology, driving a threefold increase in refractive surgery business growth and recouping the investment within 3 years.
In 2012, the acquisition of Endure Medical integrated 3D surgical microscope technology, increasing the market share of microsurgical equipment from 18% to 35%.
2014 Acquisition of WaveTec Vision: Obtained intraoperative aberrometry technology, optimized IOL implantation outcomes, and drove the growth of the multifocal IOL market.
2016 Cooperation with PowerVision: Development of Liquid-Based Adjustable Intraocular Lens to Fill the Gap in Dynamic Vision Correction.
Acquisition of Ivantis in 2021: Obtained minimally invasive glaucoma stent technology, driving annual growth of related products to 22%, far exceeding the industry average.
Full Optical Shaping Technology Launched in 2023: Personalized Myopia Surgery Achieved Through AI Algorithms, Market Share Increased by 2 Percentage Points.

These mergers and acquisitionsProduct line upgrades have been achieved through technical integration, with no major integration failures, validating its "technology-driven + clinical demand-oriented" M&A logic.

Industry Insights

For the global ophthalmology market, Alcon's acquisition of LENSAR is not only a union at the capital level, but alsoA Landmark Event in the Transition of Ophthalmic Surgical Techniques from "Experience-Dependent" to "Data-Driven".As aging accelerates and the demand for precision medicine grows, this deal is expected to reshape the competitive landscape of the global ophthalmic surgery market.

Looking at the overall trend in the medical device industry, facing acquisitions by leading companies,Ordinary enterprises can enhance their risk resistance through patent layout and ecological cooperation, while innovative enterprises should focus on scenario-based innovation and rapid iteration, using capital leverage to achieve overtaking on a curve.In the next five years, companies with AI + hardware + data closed-loop capabilities will become key acquisition targets for giants.

▲ Source of the article: Medical Device Innovation Network

▲Please indicate the source above when reprinting.

Disclaimer: This article is intended solely for the purpose of information transmission and is for reference only. It does not constitute any advice on investment or treatment; please exercise caution. If it involves issues related to the content, copyright, or other aspects of the work, to protect the rights and interests of both parties, please contact us and we will handle it immediately. If this article is reprinted by any platform, the platform must take responsibility for the article itself. The Medical Device Innovation Network is not responsible for any secondary dissemination caused by reprints.

PAST/PREVIEW

Layoffs exceed 300, even BD can't bear it, have the rice bowls "shattered all over"?

56.95 Million Yuan, United Imaging Wins Another Bid!

Market Value Breaks 10.9 Billion on the First Day of Listing, Medical Technology IPO Market Welcomes a New Benchmark